anti-PD-1 antibody + paclitaxel + carboplatin

This combination regimen consists of an unspecified anti-PD-1 monoclonal antibody, paclitaxel, and carboplatin. It is currently being evaluated in a Phase 2 clinical trial (NCT04914182) by the Sichuan Cancer Hospital and Research Institute as a neoadjuvant therapy for locally advanced thoracic solid tumors, specifically non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC). The study explores the optimal sequencing of immunotherapy and chemotherapy, comparing administration of the anti-PD-1 antibody 24 hours after chemotherapy versus concurrent administration on the first day of each cycle. The regimen leverages the synergistic effects of checkpoint inhibition (via the PD-1 antibody) and cytotoxic chemotherapy (paclitaxel and carboplatin) to improve surgical outcomes and long-term survival in patients with chest malignancies.

Other names

anti-PD-1 antibody + paclitaxel + carboplatin-Sichuan Cancer Hospital and Research Institute-non-small cell lung cancer-esophageal squamous cell carcinomaAnti-PD-1 antibody combined with Paclitaxel and carboplatinAnti-PD1 antibody combined with Paclitaxel and carboplatinAnti-PD 1 antibody combined with Paclitaxel and carboplatinNeoadjuvant CTIO